Background: This subgroup analysis of RE-ENACT study (retrospective, multicenter, observational pooled study on wet
age-related macular degeneration [wet AMD], diabetic macular edema, and retinal vein occlusion) evaluated the effectiveness
of Razumab® (world’s first biosimilar ranibizumab by Intas Pharmaceuticals Ltd., India) in Indian patients with wet
AMD.
Methods: Data of the patients with wet AMD, who were treated with ?3 injections of Razumab® between January and
August 2016, were included. Endpoints were: improvement in best corrected visual acuity (BCVA, measured by logMAR/
Snellen’s chart), decrease in central macular thickness (CMT, measured by Spectral Domain Optical Coherence Tomography),
and intraretinal fluid (IRF) and subretinal fluid (SRF) from baseline at Weeks 4, 8 and 12.
Result: Medical charts of 194 patients were analysed; 112 (57.73%) were men, 82 (42.27%) were women. Mean ± SE BCVA
improved from baseline (0.81 ± 0.03) at Week 4 (0.78 ± 0.03; p=0.13) and attained significance at Weeks 8 (0.66 ± 0.02) and
12 (0.55 ± 0.02; p<0.0001 for both time points); mean ± SE CMT significantly decreased from baseline (393.02 ± 7.32 ?m)
to Weeks 4 (385.93 ± 7.10 ?m; p=0.0041), 8 (332.75 ± 6.10 ?m; p<0.0001) and 12 (293.5 ± 4.10 ?m; p<0.0001). Proportion
of patients with IRF and SRF significantly (P<0.0001) decreased from baseline to Weeks 4, 8 and 12 (59.79% vs. 47.94%,
41.75%, and 31.96%, respectively for IRF; and 82.47% vs. 66.49%, 51.03%, 41.24%, respectively for SRF). No new safety
concerns with biosimilar ranibizumab were observed.
Conclusion: Razumab® (biosimilar ranibizumab) effectively improved the visual acuity and disease outcomes with no new
safety concerns in patients with wet age-related macular degeneration in the real world setting.
Real Time Impact Factor:
1.66667
Author Name: Dr. (Major) Shashikant Sharma
URL: View PDF
Keywords: Razumab; Efficacy; Safety; Wet Age Related Macular Degeneration; Wet AMD.
ISSN:
EISSN: 2332-290X
EOI/DOI: 10.19070/2332-290X-1800074
Add Citation
Views: 1